Show simple item record

dc.contributor.authorFarrell, Lara J.en
dc.contributor.authorWaters, Allison M.en
dc.contributor.authorOar, Ella L.en
dc.contributor.authorTiralongo, Evelinen
dc.contributor.authorGarbharran, Vinayen
dc.contributor.authorAlston-Knox, Clairen
dc.contributor.authorMcConnell, Harryen
dc.contributor.authorCollings, Nigelen
dc.contributor.authorZimmer-Gembeck, Melanieen
dc.contributor.authorDonovan, Caroline L.en
dc.contributor.authorTesta, Chrisen
dc.contributor.authorStorch, Eric A.en
dc.contributor.authorOllendick, Thomas H.en
dc.date.accessioned2019-08-16T14:07:10Zen
dc.date.available2019-08-16T14:07:10Zen
dc.date.issued2018-06en
dc.identifier.issn2162-3279en
dc.identifier.urihttp://hdl.handle.net/10919/93164en
dc.description.abstractBackground: D-Cycloserine has potential to enhance exposure therapy outcomes. The current study presents a preliminary randomized, placebo-controlled double-blind pilot trial of DCS-augmented one-session treatment (OST) for youth (7-14 years) with specific phobia. A secondary aim of this pilot study was to explore the effects of youth age and within-session fear reduction as potential moderators of DCS outcomes in order to generate hypotheses for a larger trial. It was hypothesized that DCS would be associated with greater improvements than placebo, that children (7-10 years) would have greater benefits than adolescents (11-14 years), and that DCS effects would be stronger for participants with the greater within-session fear reduction during the OST. Methods: Thirty-five children and adolescents were randomized to either OST combined with DCS (n = 17), or OST combined with placebo (PBO; n = 18) and assessed at 1 week, 1 month, and 3 month following treatment. Results: There were no significant pre- to post-treatment or follow-up benefits of DCS relative to placebo. Secondary analyses of age indicated that relative to PBO, DCS was associated with greater improvements for children (but not adolescents) on measures of severity at 1-month follow-up. Children in the DCS condition also showed significantly greater improvement to 1 month on global functioning relative to other groups. Conversely, adolescents had significant post-treatment benefits in the PBO condition on symptom severity measures relative to DCS, and adolescents in the DCS condition had significantly poorer functioning at 3 months relative to all other groups. Finally, there was a trend for within-session fear reduction to be associated with moderating effects of DCS, whereby greater reduction in fear was associated with greater functioning at one-month follow-up for children who received DCS, relative to PBO. Limitations: The study sample was small and therefore conclusions are tentative and require replication. Conclusions: Age and within-session fear reduction may be important moderators of DCS-augmented one-session exposure therapy, which requires testing in a fully powered randomized controlled trial.en
dc.description.sponsorshipGriffith University; Menzies Health Institute of QLD, Areas of Strategic Investment Fundingen
dc.format.mimetypeapplication/pdfen
dc.language.isoenen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectchildrenen
dc.subjectD-Cycloserineen
dc.subjectexposure therapyen
dc.subjectone-session treatmenten
dc.subjectphobiaen
dc.titleD-cycloserine-augmented one-session treatment of specific phobias in children and adolescentsen
dc.typeArticle - Refereeden
dc.contributor.departmentPsychologyen
dc.title.serialBrain And Behavioren
dc.identifier.doihttps://doi.org/10.1002/brb3.984en
dc.identifier.volume8en
dc.identifier.issue6en
dc.type.dcmitypeTexten
dc.identifier.pmid30106248en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution 4.0 International
License: Creative Commons Attribution 4.0 International